循环金属复合物通过PI3K/mTOR/Nrf2信号通路克服了西斯普拉丁的耐药性
Lanmei Chen1,2,3, Wenzhu Yu1,2,3, Hong Tang1,2,3
1Key Laboratory of Computer-Aided Drug Design of Dongguan City, Guangdong Key Laboratory for Research and Development of Natural Drugs, School of Pharmacy, Guangdong Medical University, Dongguan, Guangdong 523808, P. R. China.
Metallomics : integrated biometal science
|January 6, 2024
概括
新型复合物在克服非小细胞肺癌 (NSCLC) 中的西斯普拉丁耐药性方面表现有希望. 这些化合物抑制细胞增殖和耐药性机制,提供一种潜在的新型低毒性治疗.
科学领域:
- 有机金属化学 有机金属化学
- 癌症治疗方法 癌症治疗方法
- 药物耐药性 药物耐药性 药物耐药性
背景情况:
- 在治疗非小细胞肺癌 (NSCLC) 方面,西斯普拉丁耐药性是一个重大挑战.
- 需要新的治疗策略来克服NSCLC的耐药性.
研究的目的:
- 设计,合成和表征新的循环金属化Ru (II) 复合物.
- 评估这些Ru (II) 复合物的体内细胞毒性和抗癌活性,以对抗抗的肺癌细胞.
- 调查这些复合物克服西斯普拉丁耐药性的机制.
主要方法:
- 合成和描述了三个新的Ru(II) 综合体:RuIQ6,RuIQ7和RuIQ8.
- 在体外细胞毒性测试中比较Ru (II) 复合物,配体,前体和西斯.
- 通过Akt和mTOR酸化的西部斑点分析进行细胞增殖抑制研究.
- 使用qRT-PCR进行NF-E2相关因子2 (NRF2) 和MRP1.1的基因转录分析.
- 诱导亡和斑马鱼胚胎毒性测试.
主要成果:
- 在体外,RuIQ6-8的细胞毒性明显高于西斯和对照剂.
- 复合物通过降低Akt和mTOR酸化的调节来抑制A549/DDP细胞增殖.
- RuIQ6-8抑制了NRF2基因转录,降低了下游MRP1的表达,并克服了对西斯的抗性.
- 这三种Ru-IQ复合物在斑马鱼胚胎毒性测试中表现出良好的安全性.
结论:
- 这种新的Ru (II) 复合物有效地克服了NSCLC细胞中西斯普拉丁的耐药性.
- 这些复合物通过抑制增殖和耐药性途径表现出有希望的抗癌活性.
- 开发的Ru (II) 化合物代表了NSCLC治疗中潜在的创新性,低毒性治疗剂.
更多相关视频
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Electron Transport Chain: Complex I and II
13.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.5K


